A new treatment for dry eye disease is now available to local residents through St. Johns Eye Associates.
LipiFlow is a new FDA-cleared treatment for dry eye disease associated with Meibomian Gland Dysfunction (MGD). MGD is the leading cause of most forms of dry eye disease.
Dry eye disease is a progressive condition that was once thought to affect only older adults. MGD affects people of all ages, however, and is influenced by many factors, including use of digital devices and computer-intensive work environments. Research shows that fluctuating vision – having blurrier vision at certain times of the day – is one of the most common patient complaints. Other symptoms include irritated, gritty, scratchy, or burning eyes; a feeling of something in the eyes; excess watering; and blurred vision. Without treatment, experts say, dry eye disease progresses over time and ultimately can affect vision and quality of life.
Promoted as being fast and painless, LipiFlow can substantially improve the quality of life for dry eye sufferers, providing comfort to more than 85 percent of dry eye patients. What’s more, patients can use their FSA/HSA dollars towards LipiFlow.
“Dry eye is one of the most common complaints I hear from patients, and it’s one that shouldn’t be ignored,” said Dr. Sharokh Kapadia of St. Johns Eye Associates. “We are pleased to now offer LipiFlow to help those with MGD. I can’t stress enough how important it is to care for your eye health and not let dry eye go untreated. LipiFlow can bring comfort back to a dry eye sufferer’s life.”
For more information about dry eye disease or LipiFlow technology, or to schedule a treatment, contact St. Johns Eye Associates at (904) 825-4525 (Nocatee), (904) 287-9137 (St. Johns) or visit www.stjohnseyeassociates.com.
